{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T01:05:13Z","timestamp":1760144713428,"version":"build-2065373602"},"reference-count":33,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2013,6,1]],"date-time":"2013-06-01T00:00:00Z","timestamp":1370044800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,6,1]],"date-time":"2013-06-01T00:00:00Z","timestamp":1370044800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","onlinecjc.ca","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Canadian Journal of Cardiology"],"published-print":{"date-parts":[[2013,6]]},"DOI":"10.1016\/j.cjca.2012.05.013","type":"journal-article","created":{"date-parts":[[2012,7,20]],"date-time":"2012-07-20T23:26:37Z","timestamp":1342826797000},"page":"672-677","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Hemodynamic Stability After Transitioning Between Endothelin Receptor Antagonists in Patients With Pulmonary Arterial Hypertension"],"prefix":"10.1016","volume":"29","author":[{"given":"Benjamin","family":"Fox","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Langleben","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew M.","family":"Hirsch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert D.","family":"Schlesinger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark J.","family":"Eisenberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dominique","family":"Joyal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fay","family":"Blenkhorn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lyda","family":"Lesenko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.cjca.2012.05.013_bib1","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1038\/332411a0","article-title":"A novel potent vasoconstrictor peptide produced by vascular endothelial cells","volume":"332","author":"Yanagisawa","year":"1988","journal-title":"Nature"},{"key":"10.1016\/j.cjca.2012.05.013_bib2","doi-asserted-by":"crossref","first-page":"464","DOI":"10.7326\/0003-4819-114-6-464","article-title":"Increased plasma endothelin-1 in pulmonary hypertension: marker or mediator of disease?","volume":"114","author":"Stewart","year":"1991","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.cjca.2012.05.013_bib3","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1056\/NEJM199306173282402","article-title":"Expression of endothelin-1 in the lungs of patients with pulmonary hypertension","volume":"328","author":"Giaid","year":"1993","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cjca.2012.05.013_bib4","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.ccm.2006.11.002","article-title":"Endothelin receptor antagonists in the treatment of pulmonary arterial hypertension","volume":"28","author":"Langleben","year":"2007","journal-title":"Clin Chest Med"},{"key":"10.1016\/j.cjca.2012.05.013_bib5","doi-asserted-by":"crossref","first-page":"2250","DOI":"10.1161\/CIRCULATIONAHA.109.192230","volume":"119","author":"McLaughlin","year":"2009","journal-title":"Circulation"},{"issue":"supp B","key":"10.1016\/j.cjca.2012.05.013_bib6","first-page":"5B","article-title":"Pulmonary hypertension: classification and treatment","volume":"26","author":"Channick","year":"2010","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.cjca.2012.05.013_bib7","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1056\/NEJMoa012212","article-title":"Bosentan therapy for pulmonary arterial hypertension","volume":"346","author":"Rubin","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cjca.2012.05.013_bib8","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1164\/rccm.200307-957OC","article-title":"Sitaxsentan therapy for pulmonary arterial hypertension","volume":"169","author":"Barst","year":"2004","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.cjca.2012.05.013_bib9","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.1016\/j.jacc.2009.07.033","article-title":"Long-term ambrisentan therapy for the treatment of pulmonary arterial hypertension","volume":"54","author":"Oudiz","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cjca.2012.05.013_bib10","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1378\/chest.07-0767","article-title":"Sitaxsentan for the treatment of pulmonary arterial hypertension: a 1-year, prospective, open-label observation of outcome and survival","volume":"134","author":"Benza","year":"2008","journal-title":"Chest"},{"key":"10.1016\/j.cjca.2012.05.013_bib11","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1183\/09031936.00194810","article-title":"Liver toxicity of sitaxentan in pulmonary arterial hypertension","volume":"37","author":"Gali\u00e8","year":"2011","journal-title":"Eur Respir J"},{"key":"10.1016\/j.cjca.2012.05.013_bib12","doi-asserted-by":"crossref","first-page":"119","DOI":"10.2147\/VHRM.S15026","article-title":"Effect of transition from sitaxsentan to ambrisentan in pulmonary arterial hypertension","volume":"7","author":"Safdar","year":"2011","journal-title":"Vasc Health Risk Manag"},{"key":"10.1016\/j.cjca.2012.05.013_bib13","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1378\/chest.08-1028","article-title":"Ambrisentan therapy in patients with pulmonary arterial hypertension who discontinued bosentan or sitaxsentan due to liver function test abnormalities","volume":"135","author":"McGoon","year":"2009","journal-title":"Chest"},{"key":"10.1016\/j.cjca.2012.05.013_bib14","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.healun.2006.10.019","article-title":"Sitaxsentan treatment for patients with pulmonary arterial hypertension failing bosentan treatment","volume":"26","author":"Benza","year":"2007","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.cjca.2012.05.013_bib15","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1136\/thx.39.11.818","article-title":"Effect of encouragement on walking test performance","volume":"39","author":"Guyatt","year":"1984","journal-title":"Thorax"},{"issue":"suppl B","key":"10.1016\/j.cjca.2012.05.013_bib16","first-page":"12B","article-title":"Outcomes in pulmonary hypertension: beyond 40 metres","volume":"26","author":"Granton","year":"2010","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.cjca.2012.05.013_bib17","article-title":"Pfizer initiates product withdrawal of Thelin (sitaxsentan sodium) worldwide","author":"Prigent","year":"2011","journal-title":"Health Canada TechReport"},{"key":"10.1016\/j.cjca.2012.05.013_bib18","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/j.rmed.2007.12.020","article-title":"Long-term experience after transition from parenteral prostanoids to oral agents in patients with pulmonary hypertension","volume":"102","author":"Diaz-Guzman","year":"2008","journal-title":"Respir Med"},{"key":"10.1016\/j.cjca.2012.05.013_bib19","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1164\/rccm.200505-766OC","article-title":"Transition from intravenous epoprostenol to intravenous treprostinil in pulmonary hypertension","volume":"172","author":"Gomberg-Maitland","year":"2005","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.cjca.2012.05.013_bib20","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1016\/j.healun.2007.07.040","article-title":"Safety and efficacy of transition from subcutaneous treprostinil to oral sildenafil in patients with pulmonary arterial hypertension","volume":"26","author":"Keogh","year":"2007","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.cjca.2012.05.013_bib21","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1016\/j.amjcard.2009.12.075","article-title":"Effectiveness of transition from intravenous epoprostenol to oral\/inhaled targeted pulmonary arterial hypertension therapy in pediatric idiopathic and familial pulmonary arterial hypertension","volume":"105","author":"Melnick","year":"2010","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.cjca.2012.05.013_bib22","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1111\/j.1751-7133.2008.00006.x","article-title":"Successful transition from intravenous to inhaled prostacyclin in a patient with pulmonary hypertension and right ventricular failure","volume":"14","author":"Reddy","year":"2008","journal-title":"Congest Heart Fail"},{"key":"10.1016\/j.cjca.2012.05.013_bib23","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1345\/aph.1E418","article-title":"Staggered transition to epoprostenol from treprostinil in pulmonary arterial hypertension","volume":"39","author":"Reisbig","year":"2005","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.cjca.2012.05.013_bib24","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1016\/j.rmed.2009.05.009","article-title":"Outcome of pulmonary hypertension subjects transitioned from intravenous prostacyclin to oral bosentan","volume":"103","author":"Safdar","year":"2009","journal-title":"Respir Med"},{"key":"10.1016\/j.cjca.2012.05.013_bib25","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1378\/chest.119.1.296","article-title":"Aerosolized iloprost therapy could not replace long-term IV epoprostenol (prostacyclin) administration in severe pulmonary hypertension","volume":"119","author":"Schenk","year":"2001","journal-title":"Chest"},{"key":"10.1016\/j.cjca.2012.05.013_bib26","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/FJC.0b013e31802b3184","article-title":"Rapid switch from intravenous epoprostenol to intravenous treprostinil in patients with pulmonary arterial hypertension","volume":"49","author":"Sitbon","year":"2007","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1016\/j.cjca.2012.05.013_bib27","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1378\/chest.130.5.1471","article-title":"Conversion to bosentan from prostacyclin infusion therapy in pulmonary arterial hypertension: a pilot study","volume":"130","author":"Steiner","year":"2006","journal-title":"Chest"},{"key":"10.1016\/j.cjca.2012.05.013_bib28","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1378\/chest.126.3.808","article-title":"Transition from epoprostenol and treprostinil to the oral endothelin receptor antabonist bosentan in patients with pulmonary hypertension","volume":"126","author":"Suleman","year":"2004","journal-title":"Chest"},{"key":"10.1016\/j.cjca.2012.05.013_bib29","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1378\/chest.121.5.1561","article-title":"Transitioning from i.v. epoprostenol to subcutaneous treprostinil in pulmonary arterial hypertension","volume":"121","author":"Vachiery","year":"2002","journal-title":"Chest"},{"key":"10.1016\/j.cjca.2012.05.013_bib30","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1164\/rccm.200410-1411OC","article-title":"Sildenafil versus Endothelin Receptor Antagonist for Pulmonary Hypertension (SERAPH) study","volume":"171","author":"Wilkins","year":"2005","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.cjca.2012.05.013_bib31","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1164\/ajrccm.166.1.at1102","article-title":"ATS statement: guidelines for the six-minute walk test","volume":"166","year":"2002","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.cjca.2012.05.013_bib32","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.vph.2005.03.003","article-title":"The 6-min walk test (6MW) as an efficacy endpoint in pulmonary arterial hypertension clinical trials: demonstration of a ceiling effect","volume":"43","author":"Frost","year":"2005","journal-title":"Vascul Pharmacol"},{"key":"10.1016\/j.cjca.2012.05.013_bib33","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1111\/j.1440-1681.2011.05517.x","article-title":"New concepts in endothelin control of sodium balance","volume":"39","author":"Nakano","year":"2011","journal-title":"Clin Exp Pharmacol Physiol"}],"container-title":["Canadian Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0828282X12002747?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0828282X12002747?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T14:37:59Z","timestamp":1760107079000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0828282X12002747"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,6]]},"references-count":33,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2013,6]]}},"alternative-id":["S0828282X12002747"],"URL":"https:\/\/doi.org\/10.1016\/j.cjca.2012.05.013","relation":{},"ISSN":["0828-282X"],"issn-type":[{"type":"print","value":"0828-282X"}],"subject":[],"published":{"date-parts":[[2013,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Hemodynamic Stability After Transitioning Between Endothelin Receptor Antagonists in Patients With Pulmonary Arterial Hypertension","name":"articletitle","label":"Article Title"},{"value":"Canadian Journal of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cjca.2012.05.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Canadian Cardiovascular Society. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}